MicroMed predicts Q4 start for DELTA ONE trial:
This article was originally published in Clinica
MicroMed Technology has submitted an investigational device exemption (IDE) application to the US FDA to start a clinical trial to assess its miniaturised cardiac assist device as a long-term treatment for heart failure patients who are not eligible for heart transplantation. The DeBakey ventricular assist device is currently being tested in a pivotal trial in the US as a bridge to transplant and is already approved for sale in Europe. The Houston, Texas firm said that pending FDA approval of the IDE, it planned to begin the new trial, called DELTA ONE, by the fourth quarter of 2002.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.